Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHOC | P08134 | 2/20 | 0.56 |
| ▸ | RHOA | P61586 | 2/20 | 0.56 |
| ▸ | TACR1 | P25103 | 4/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | MTOR | P42345 | 2/20 | 0.44 |
| ▸ | MC4R | P32245 | 2/20 | 0.43 |
| ▸ | MC5R | P33032 | 2/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.41 |
| ▸ | MLYCD | O95822 | 1/20 | 0.40 |
| ▸ | MC3R | P41968 | 1/20 | 0.38 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.36 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5084706 | 0.83 | TACR1 (0.59) | RHOCRHOATACR1IDO1MTOR | |
| SCHEMBL19300959 | 0.83 | SIGMAR1 (0.46) | RHOCRHOATACR1IDO1TAAR1 | |
| SCHEMBL7249965 | 0.82 | TAAR1 (0.62) | IDO1MC4RMC5RTAAR1SCN8A | |
| SCHEMBL4256377 | 0.81 | RHOC (0.57) | RHOCRHOATACR1IDO1MTOR | |
| SCHEMBL6948873 | 0.81 | RHOC (0.57) | RHOCRHOATACR1IDO1MTOR | |
| SCHEMBL8350245 | 0.81 | TAAR1 (0.57) | RHOCRHOAIDO1MTORMC4R | |
| SCHEMBL4260305 | 0.81 | RHOC (0.53) | RHOCRHOATACR1IDO1MTOR | |
| SCHEMBL16264598 | 0.81 | RHOC (0.50) | RHOCRHOATACR1MTORMC4R | |
| SCHEMBL24477135 | 0.79 | MC4R (0.55) | MC4RMC5RMC3R | |
| SCHEMBL19300873 | 0.77 | RHOC (0.41) | RHOCRHOATACR1IDO1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017147335-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-08-31 | — | — | WO | disclosed |
| EP-0733632-B1 | Cyclic compounds, their production and use as tachykinin receptor antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-06-04 | — | — | EP | disclosed |
| US-6489315-B1 | NOVEL CYCLIC COMPOUNDS HAVING AN EXCELLENT TACHYKININ RECEPTOR ANTAGONISTIC EFFECT, AND A METHOD FOR PRODUCING THEM, FOR TREATING DISORDERS OF INCONTINENCE, ASTHMA, MIGRAINE, IRRITABLE BOWEL SYNDROME, PAIN, COUGH OR EMESIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-12-03 | — | — | US | disclosed |
| US-20020132817-A1 | Heterocyclic compounds, their production and use | NATSUGARI HIDEAKI (JP) | 2002-09-19 | — | — | US | disclosed |
| EP-1184036-A2 | Heterocyclic compounds, their production and use as tachykinin receptor antagonists | Takeda Chemical Industries, Ltd. (JP) | 2002-03-06 | — | — | EP | disclosed |
| EP-1145714-A1 | DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2001-10-17 | — | — | EP | disclosed |
| CN-1291099-A | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-04-11 | — | — | CN | disclosed |
| EP-1061926-A2 | HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE AS TACHYKININ RECEPTOR ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2000-12-27 | — | — | EP | disclosed |
| US-6147071-A | TACHYKININ RECEPTOR ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-11-14 | — | — | US | disclosed |
| WO-1999047132-A2 | HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE AS TACHYKININ RECEPTOR ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-09-23 | — | — | WO | disclosed |
| US-5770590-A | EXCELLENT TACHYKININ RECEPTOR ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-06-23 | — | — | US | disclosed |
| EP-0733632-A1 | Cyclic compounds, their production and use as tachykinin receptor antagonists | Takeda Chemical Industries, Ltd. (JP) | 1996-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132817-A1 | Heterocyclic compounds, their production and use | CRH, CRHR1, CRHR2 | RHOC 2512/4885RHOA 1520/4885TACR1 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.